Jan 29 2010
Quintiles
today announced a strategic alliance with Movetis
NV for commercialization of its new product, Resolor (prucalopride), in
the U.K. and Germany. Under the alliance, Quintiles will execute a
comprehensive commercial
sales effort for the product launch and provide additional services in
consulting, market access, market intelligence and analytics, regulatory
and post-marketing pharmacovigilance. The agreement is expected to be
extended later this year to cover other selected European countries.
“We are confident that our alliance with
Quintiles will help drive our goal of becoming a successful European
specialty GI company. The launch of Resolor will be a key milestone as
we continue to build on our expertise in bringing new GI drugs from
discovery to marketing.”
Movetis is a European specialty pharmaceutical company focused on the
discovery, development and commercialization of proprietary and
innovative drugs for the treatment of diseases in the gastrointestinal
(GI) area. Movetis obtained approval for the commercialization of
Resolor in the European Economic Area for the symptomatic treatment of
chronic constipation for women in whom laxatives fail to provide
adequate relief.
Chris Pepler, Senior Vice President of Global Business Development and
Operations for Quintiles said: “This agreement is an example of how
leading specialty pharma companies are building partnerships that extend
beyond the traditional Commercial Sales Organization model to manage
risk, increase productivity, overcome complexity and demonstrate value
to stakeholders in the New Health. We are pleased that Movetis has
chosen to leverage Quintiles’ suite of comprehensive services, including
our product and brand solutions, to help ensure the commercial success
of Resolor.”
Movetis CEO Dirk Reyn said: “We are confident that our alliance with
Quintiles will help drive our goal of becoming a successful European
specialty GI company. The launch of Resolor will be a key milestone as
we continue to build on our expertise in bringing new GI drugs from
discovery to marketing.”
Source: Quintiles
Diabetes remission possible with GLP-1 drugs, Italian study confirms